Cyrcadia Health

What Cyrcadia Health does

Cyrcadia Health is a Reno, Nevada-based privately held medical device company developing the Cyrcadia Breast Monitor, a non-invasive, non-compressive, non-radiogenic wearable breast health screening system. Each unit consists of two conformable patches containing eight embedded digital temperature sensors that capture thermo-circadian rhythm alterations in breast tissue over a 6-24 hour wear period. Captured data is transmitted via Bluetooth to a mobile device and then to a cloud-based Core Lab hosted on Microsoft Azure, where proprietary patented machine learning analytics categorize abnormal circadian temperature patterns to flag early breast tissue abnormalities.

The company targets early breast cancer detection, with particular emphasis on the dense breast tissue population (approximately 40% of women) where mammography sensitivity has been reported at 42.9% in clinical data versus Cyrcadia's reported 85.7% sensitivity. Updated analytics show 84% accuracy, 90.16% sensitivity, and 84% specificity. Clinical validation has been conducted across multiple sites including Ohio State University James Cancer Hospital, El Camino Hospital (173-patient pilot), Clem Plam Breast Clinic in Argentina, and Green Memorial Hospital in Ohio. Three registered patents covering the core circadian-rhythm detection science are held through Lifeline Biotechnologies (LLBO), a publicly traded entity that owns approximately 30% of Cyrcadia.

Name

Cyrcadia Health

Legal name

Cyrcadia Health

Website

https://cyrcadiahealth.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Cyrcadia Health is a pre-commercial medical device company developing the Cyrcadia Breast Monitor, a wearable breast health screening system using temperature sensors and machine learning analytics to detect early tissue abnormalities, particularly for women with dense breast tissue.

Ownership category

akta.pro rank

Product category

Wearable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industries

Thermometers & Temperature Monitoring (Smart Thermometers) (CRACAQAG), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)

Keywords

• Wearable medical devices
• Breast cancer screening
• Early detection technology
• Digital health monitoring
• Predictive health analytics

Headquarters

HQ city

Reno

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Distribution channels1 record

Marketing channels3 records

Core offering

Cyrcadia Health develops the Cyrcadia Breast Monitor, a non-invasive, non-compressive, non-radiogenic wearable medical device consisting of two intelligent breast patches with embedded digital temperature sensors that capture circadian rhythm changes in breast tissue over 6-24 hours. Data is transmitted via Bluetooth to a mobile app and sent to a cloud-based Core Lab where proprietary machine learning predictive analytics analyze thermo-circadian patterns to detect early breast tissue abnormalities, with results delivered to healthcare providers. The product is not currently available for sale in the United States.

Product overview

Cyrcadia Health offers a single unified wearable medical device product called the Cyrcadia Breast Monitor (formerly known as the Circadian Biometric Recorder/CBR). The system consists of wearable breast patches with embedded temperature sensors, a Bluetooth-enabled Data Recording Device (DRD), a Cyrcadia Mobile Application for data transfer, and a cloud-based Core Lab with proprietary patented analytics framework. The product works as an adjunct solution to current accepted imaging technologies for early breast health monitoring, capturing thermo-circadian rhythm alterations over time (four-dimensional system: time, temperature, sensor X and Y locations) to detect early breast tissue abnormalities without radiation or compression.

Differentiator

Problem solved

Functional benefit

Brands

• Cyrcadia Breast Monitor: Wearable breast monitoring device consisting of two comfortable intelligent breast patches which identify circadian temperature changes over time within breast tissue. Formerly known as Circadian Biometric Recorder (CBR).

Products and services

• Cyrcadia Breast Monitor

Quantifiable outcome

• 91% sensitivity (21 of 23 cancers detected) compared to 83% for mammography in initial studies
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core, regional and minor.

• Nanyang Technological University (NTU) SingaporecoreStrategic or Co-development PartnerCyrcadia's predictive analytics were developed out of Nanyang Technological University in Singapore. The university collaborated on over eight years of additional predictive analytic analysis with Cyrcadia's engineering team. The core technology was developed in conjunction with NTU researchers including Dr. Vinitha Sree Subbhuraam who conducted doctoral research using Cyrcadia's clinical trial datasets.
• El Camino HospitalcoreStrategic or Co-development PartnerEl Camino Hospital in Mountain View, CA served as a pilot study site for validation of the Cyrcadia Breast Monitor with 173 patients enrolled. Dr. Shyamali Mallick Singhal serves as Acting Chief Medical Officer and is a Surgical Oncologist at El Camino Cancer Hospital.
• Cyrcadia AsiaregionalChannel Partner/ Reseller/ DistributorCyrcadia Asia represents the company's presence and potential distribution channel for Asian markets.
• Ohio State UniversitycoreStrategic or Co-development PartnerOSU served as a key clinical trial site for initial Phase I and II studies, and subsequently for pilot validation studies. The initial clinical studies achieved 91% sensitivity compared to 83% for mammography.
• Lotus365minorOthersListed as a partner on the Cyrcadia Health website under the Partners section.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• iCAD: AI-driven breast health solutions including breast density assessment and cancer detection software used alongside mammography. Directly comparable to Cyrcadia as a technology-enabled adjunct to standard breast imaging.
• Volpara Health Technologies: Provides breast density assessment and cancer risk analytics software serving mammography practices. Comparable to Cyrcadia in targeting the dense-breast-tissue clinical gap with software-driven measurement.
• UE LifeSciences: Developer of iBreastExam, a handheld radiation-free breast lesion detection device used in low-resource and adjunctive settings. Closest direct comparator to Cyrcadia as a non-invasive, radiation-free breast screening device serving similar end users.

Emerging players

• QT Ultrasound: Developer of transmission ultrasound for radiation-free breast imaging as an alternative/complement to mammography. Comparable as an emerging non-ionizing breast imaging modality.
• Densitas: AI company focused on breast density measurement and mammography quality analytics. Adjacent technology player in the same dense-breast clinical workflow that Cyrcadia targets.
• Delphinus Medical Technologies: Developer of SoftVue, a whole-breast ultrasound tomography system for supplemental breast cancer screening in dense tissue. Comparable as a dense-tissue supplemental breast imaging technology.
• Niramai Health Analytix: India-based developer of a thermal imaging-based, non-invasive breast cancer screening solution. Comparable to Cyrcadia in using temperature/thermal data and AI to detect breast abnormalities without radiation or compression.
• iSono Health: Maker of a portable, automated whole-breast ultrasound system for radiation-free breast screening. Comparable emerging competitor pursuing non-invasive, radiation-free breast screening outside of standard mammography.

Broad incumbents

• Hologic: Dominant incumbent in mammography (3Dimensions, Genius 3D) and breast biopsy. The entrenched standard-of-care player whose dense-tissue limitations Cyrcadia's data specifically challenges.
• GE HealthCare: Major mammography and breast imaging incumbent (Senographe systems) with broad women's health portfolio. Comparable as the large incumbent against whose installed base Cyrcadia would compete for adjunctive screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CyrcadiaHealth
• Facebookfacebook.com/cyrcadia

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyrcadia Health